Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Phase 2

Completed

• Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
• Interventions: Drug: triapine

• Registration Number: NCT00085371
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas. Drugs used in chemotherapy, such as triapine, work in different ways to stop tumor cells from dividing so they stop growing or die.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the 3- and 6-month survival rate of patients with locally advanced or metastatic adenocarcinoma of the pancreas treated with 3-AP (Triapine\^®) as first- or second-line therapy.

SECONDARY OBJECTIVES:

I. Determine the toxicity and tolerability of this drug in these patients. II. Determine the time to treatment failure in patients treated with this drug. III. Determine overall survival and disease progression in patients treated with this drug.

IV. Determine tumor response in patients treated with this drug. V. Determine laboratory studies that will increase our understanding of Triapine and its effects on cellular processes.

OUTLINE: This is a multicenter study. Patients are stratified according to prior chemotherapy (yes vs no).

Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3-6 months for 3 years.

Study Timeline

• Study First Submitted: 2004-06-10
• Study First Submitted QC: 2004-06-10
• Study First Posted: 2004-06-11
• Study Start: 2004-07
• Primary Completion: 2006-07
• Status Verified: 2013-10
• Last Update Submitted: 2013-10-07
• Last Update Posted: 2013-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Histologically or cytologically confirmed adenocarcinoma of the pancreas

  • Unresectable disease
  • Locally advanced or metastatic disease

• At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

  • Measurable lesions outside prior radiotherapy field OR measurable lesions actively growing in the site of prior radiotherapy

• No prior chemotherapy OR previously treated with 1, and only 1, gemcitabine-containing regimen for metastatic, unresectable, or locally advanced pancreatic cancer

  • Adjuvant therapy not considered prior chemotherapy if all treatment was completed > 6 months before tumor recurrence

• No known brain metastases

• Performance status - ECOG 0-2

• At least 6 weeks

• Absolute neutrophil count >= 1,500/mm^3

• Platelet count >= 75,000/mm^3

• AST =< 3 times upper limit of normal (ULN)

• Bilirubin =< 1.5 times ULN

• Creatinine =< 1.5 times ULN

• Creatinine clearance > 60 mL/min

• No uncontrolled congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• No pulmonary disease requiring oxygen

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No glucose-6-phosphate dehydrogenase (G6PD) deficiency (for patients of African, Asian, or Mediterranean origin or ancestry)

• No active or ongoing infection

• No hypersensitivity or severe allergic reaction to 3-AP (Triapine®) or related compounds

• No concurrent uncontrolled illness

• No psychiatric illness or social situation that would preclude study compliance

• No other concurrent antineoplastic therapy

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No other concurrent investigational therapy for the malignancy

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (triapene)	triapine	Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Survival in patients receiving triapine as first-line therapy	6 months	The point estimate of the success rates will be calculated as the number of successes divided by the number of evaluable patients, with confidence intervals calculated by the method of Duffy and Santner.
Survival in patients receiving triapine as second-line therapy	4 months	The point estimate of the success rates will be calculated as the number of successes divided by the number of evaluable patients, with confidence intervals calculated by the method of Duffy and Santner.

Secondary Outcome Measures

Name	Time	Method
Confirmed tumor response, defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart	6 months (first 6 courses of treatment)
Incidence of adverse events assessed using CTCAE version 3.0	Up to 3 years
Time to treatment failure	Time from the date of randomization to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 3 years
Overall survival	Up to 3 years
Time to disease progression	Time from registration to documentation of disease progression, assessed up to 3 years	The distribution of time to progression will be estimated using the method of Kaplan-Meier.

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States